Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

BioCryst Reveals Favorable Results From Ulodesine In Phase II Clinical Trials

BioCryst Pharmaceuticals Inc (BCRX: Quote) Tuesday released positive results from the extension phase of its randomized Phase 2b trial of ulodesine added to allopurinol in patients with gout, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.

The pharmaceutical company engaged in the design, optimization and development of novel small molecule drugs, revealed that the results of the 52-week, blinded Phase 2b safety extension trial confirm that ulodesine continues to be generally safe and well-tolerated in gout patients who inadequately responded to allopurinol alone, many of which had multiple co-morbidities. No clinical adverse event signals were observed that distinguished ulodesine from placebo, either by type or by rate at the doses tested.

Ulodesine is a novel enzyme inhibitor with the potential for once-a-day oral dosing suitable for chronic administration to treat gout. It acts upstream of xanthine oxidase (XO) in the purine metabolism pathway to reduce new formation of uric acid in patients with gout.

Click here to receive FREE breaking news email alerts for Biocryst Pharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.